Replies to post #127121 on Biotech Values

[ariadndndough]

acgood here is the link to analyst day great with slides on 113.
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-IRhome



also biomaven and rkrw are the experts on aria not me so they might be better to ask if you have further questions. but that link is good place to start.

dough

[BTH]

"we can build a global oncology company"

Hows that working out for Dendreon?

[biomaven0]

link handy to any presentations on 113

This 2010 AACR poster gives good pre-clinical insight into the ALK side of things:

http://www.ariad.com/pdf/AP26113_AACR_2010_Riveraetal.pdf

[NP1986]

I'm interested to learn more about their magical block everything in the world pill.

Well, as far as we know it's only ALK and activated EGFR that it blocks. It does seem rather serendipitous that it blocks two pathways that have been implicated in non-small cell lung cancer, but lest we forget, so does crizotinib (c-MET and ALK). The question in my mind is what else, if anything, does '113 block at nanomolar concentrations? I think once the preliminary safety data are out, and if there are no worrying off-target effects, then I will be quite confident about the prospects of this drug.